Nepsone
Intro
Nepsone is a preclinical-stage pharmaceutical company developing drugs to treat dermatological conditions that arise due to an imbalance in the autonomic nervous system.
Currently, these conditions are believed to originate in the immune system. Nepsone foundational neuroimmunology theory on the origin of psoriasis teaches us that an imbalance in neuropeptide activity in the body leads to these conditions.
Our drugs are designed to utilize the body’s natural mechanisms to bring back balance and alleviate the disease.
Technology Development Fund (Rannís)
Nepsone ehf has been awarded a grant from Tækniþróunarsjóður (Technology Development Fund) of Rannís (The Icelandic Centre for Research).
Pipeline
Nepsone’s drug discovery platform can potentially address over 10 indications in total.
Psoriasis (Lead Indication)
Phase: Preclinical
Modalities: Topical and Systemic
Alopecia Areata
Phase: Research and Discovery
Modality: Topical
There are currently no approved drugs for the treatment of alopecia areata.
Eczema (Atopic Dermatitis)
Phase: Research and Discovery
Modality: Topical
The People of Nepsone
Bjarki Gudlaugsson
COO
Svandis Kristjansdottir
Head of Clinical Development
Hakon Hrafn Sigurdsson
Head of R&D
Gunhild L Skovgaard
Head of Medical Affairs
Tomas Thorvaldsson
Chairman of the board
Birkir Sveinsson
Founder / Member of the board
Ragnar Bjarnason
Member of the board